Data resources in PKD research
The PKD Foundation is dedicated to the support and advancement of PKD research. The FDA approval of total kidney volume as a biomarker for ADPKD progression demonstrated the value of data sharing in enhancing and accelerating research towards new treatments. By encouraging utilization of existing datasets, the Foundation hopes to bring new perspectives from the re-analysis of past PKD studies and utilization of ongoing data resources to contribute to a cost-effective and efficient resource for advancing research in PKD.
Consortium for Radiologic Imaging Studies of PKD (CRISP)
CRISP was established to develop and implement studies to test whether imaging techniques can provide accurate and reproducible markers of progression of renal disease in patients with ADPKD. The cohort study longitudinally observed ADPKD individuals using high-resolution magnetic resonance (MR) imaging to determine if change in renal and cyst volumes can be detected over time, and if they correlate with decline in renal function.
Find more details on CRISP and how to access study specimens and datasets here.
The HALT Progression of PKD (HALT-PKD)
The HALT-PKD studies are two simultaneous multicenter clinical trials designed to test the efficacy of aggressive renin-angiotestin-aldosterone system (RAAS) blockade and rigorous vs standard blood pressure targets on the ADPKD progression.
Find more details on HALT-PKD and how to access study specimens and datasets here.
The Critical Path Institute’s PKD Outcomes Consortium (PKDOC)
The PKDOC database consists of de-identified data from three longitudinal observational patient registries. The data have been standardized and aggregated into a common format using a Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM) structure. This enables analyses to be performed on a larger expanded dataset. The data cover approximately seven decades of patient visits from 2,498 subjects in patient registries at the University of Colorado – Denver, Mayo Clinic and Emory University.
Find more details on PKDOC and how to access study datasets here.
The Mayo Clinic ADPKD Mutation Database
The ADPKD Database (PKDB) has been established to facilitate the characterization of ADPKD variants in PKD1 and PKD2, the two major causative ADPKD genes. It has been set up as a repository of all variants in these genes, whether likely disease causing or not.
Find more details on PKDB and how to access mutation datasets here.
Rare Disease Cures Accelerator-Data and Analytics Platform
The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) is an FDA-funded initiative that provides a centralized and standardized infrastructure to support and accelerate rare disease characterization, with the goal of accelerating therapy development across rare diseases. RDCA-DAP promotes the sharing of existing patient-level data and encourages the standardization of new data collection. By integrating such data in a regulatory-grade format suitable for analytics, RDCA-DAP accelerates the understanding of disease progression (including sources of variability to optimize the characterization of subpopulations), clinical outcome measures and biomarkers, and facilitates the development of mathematical models of disease and innovative clinical trial designs.
Find more details on RDCA-DAP and how to access the platform here.
German Mutation Database ARPKD/PKHD1
The ARPKD/PKHD1 Database recognizes that it has been crucial to catalogue all changes detected in the PKHD1 gene in a locus specific database to provide the users with information on all known variants and therefore to facilitate the characterization of detected PKHD1 variants. The database has been set up to be a collection of all variants in this gene, whether they are likely disease causing or not.
Find more details on the Mutation Database and how to access ARPKD datasets here.
Page last edited January 26, 2022